Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...